DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS

• Main Authors: ST CROIX, BRAD, SEAMAN, STEVEN
• Format: Patent
• Language: English; French
• Published: 15.01.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat 10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII.alpha.1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed. L'invention concerne des procédés d'inhibition d'une angiogénèse pathologique chez un sujet. Dans des exemples particuliers, le procédé comprend l'administration d'une quantité thérapeutiquement efficace d'une composition à un sujet, la composition comprenant un agent de liaison spécifique qui se lie de préférence à une ou plusieurs protéines marqueurs de l'angiogenèse pathologique comprenant Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, ubiquitine D (Fat 10), Doppel (prion-PLP), apéline, Plgf, Ptprn (IA-2), CD109, ankylose et collagène VIII.alpha.1. Dans des exemples supplémentaires, des procédés de distribution d'un agent thérapeutique à une cellule endothéliale cérébrale ou hépatique sont également présentés.